Jüni P, Witschi A, Bloch R, Egger M
Clinical Epidemiology Study Group, Institute for Medical Education, University of Berne, Switzerland.
JAMA. 1999 Sep 15;282(11):1054-60. doi: 10.1001/jama.282.11.1054.
Although it is widely recommended that clinical trials undergo some type of quality review, the number and variety of quality assessment scales that exist make it unclear how to achieve the best assessment.
To determine whether the type of quality assessment scale used affects the conclusions of meta-analytic studies.
Meta-analysis of 17 trials comparing low-molecular-weight heparin (LMWH) with standard heparin for prevention of postoperative thrombosis using 25 different scales to identify high-quality trials. The association between treatment effect and summary scores and the association with 3 key domains (concealment of treatment allocation, blinding of outcome assessment, and handling of withdrawals) were examined in regression models.
Pooled relative risks of deep vein thrombosis with LMWH vs standard heparin in high-quality vs low-quality trials as determined by 25 quality scales.
Pooled relative risks from high-quality trials ranged from 0.63 (95% confidence interval [CI], 0.44-0.90) to 0.90 (95% CI, 0.67-1.21) vs 0.52 (95% CI, 0.24-1.09) to 1.13 (95% CI, 0.70-1.82) for low-quality trials. For 6 scales, relative risks of high-quality trials were close to unity, indicating that LMWH was not significantly superior to standard heparin, whereas low-quality trials showed better protection with LMWH (P<.05). Seven scales showed the opposite: high quality trials showed an effect whereas low quality trials did not. For the remaining 12 scales, effect estimates were similar in the 2 quality strata. In regression analysis, summary quality scores were not significantly associated with treatment effects. There was no significant association of treatment effects with allocation concealment and handling of withdrawals. Open outcome assessment, however, influenced effect size with the effect of LMWH, on average, being exaggerated by 35% (95% CI, 1%-57%; P= .046).
Our data indicate that the use of summary scores to identify trials of high quality is problematic. Relevant methodological aspects should be assessed individually and their influence on effect sizes explored.
尽管广泛建议临床试验应接受某种形式的质量审查,但现有的质量评估量表数量众多且种类繁杂,这使得如何进行最佳评估并不明确。
确定所使用的质量评估量表类型是否会影响荟萃分析研究的结论。
对17项比较低分子量肝素(LMWH)与标准肝素预防术后血栓形成的试验进行荟萃分析,使用25种不同量表来识别高质量试验。在回归模型中检验治疗效果与汇总评分之间的关联以及与3个关键领域(治疗分配的隐藏、结局评估的盲法以及失访处理)的关联。
根据25种质量量表确定的高质量试验与低质量试验中,LMWH与标准肝素相比的深静脉血栓形成的合并相对风险。
高质量试验的合并相对风险范围为0.63(95%置信区间[CI],0.44 - 0.90)至0.90(95% CI,0.67 - 1.21),而低质量试验为0.52(95% CI,0.24 - 1.09)至1.13(95% CI,0.70 - 1.82)。对于6种量表,高质量试验的相对风险接近1,表明LMWH并不显著优于标准肝素,而低质量试验显示LMWH具有更好的保护作用(P <.05)。7种量表显示出相反的情况:高质量试验显示出效果,而低质量试验则没有。对于其余12种量表,在两个质量分层中的效果估计相似。在回归分析中,汇总质量评分与治疗效果无显著关联。治疗效果与分配隐藏和失访处理无显著关联。然而,开放的结局评估影响效应大小,LMWH的效应平均被夸大35%(95% CI,1% - 57%;P = 0.046)。
我们的数据表明,使用汇总评分来识别高质量试验存在问题。应分别评估相关的方法学方面,并探讨它们对效应大小的影响。